Pfizer XTANDI Plus Androgen Deprivation Therapy Meets Endpoint In ARCHES Trial

Pfizer: XTANDI Plus Androgen Deprivation Therapy Meets Endpoint In ARCHES Trial

17:40 EST 11 Feb 2019 | FinanzNachrichten

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY) announced the results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer, or mHSPC....

More From BioPortfolio on "Pfizer: XTANDI Plus Androgen Deprivation Therapy Meets Endpoint In ARCHES Trial"